This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Glaxo's Zejula Gets Positive CHMP View for First-Line Setting
by Zacks Equity Research
The CHMP's favorable response recommends the regulatory nod for GlaxoSmithKline's (GSK) Zejula as the first-line maintenance treatment of ovarian cancer patients regardless of the biomarker status.
Novartis Announces Data on Tafinlar, Mekinist & Piqray at ESMO
by Zacks Equity Research
Novartis (NVS) announces data from late-stage studies on Tafinlar, Mekinist and Piqray at ESMO 2020.
Healthcare ETFs, Stocks That Gained Double Digits Last Week
by Sweta Killa
The healthcare sector defied last week's market rout buoyed by the progress in the development of a coronavirus vaccine or treatment, and merger and acquisition news.
4 Best-Performing Sector ETFs of Last Week
by Sanghamitra Saha
The S&P 500, the Dow Jones and the Nasdaq Composite have lost about 0.6%, 0.03% and 0.6%, respectively, past week.
Top Research Reports for Apple, Amazon & Chevron
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), Amazon.com (AMZN) and Chevron (CVX).
Pharma Stock Roundup: AZN, LLY & PFE's Coronavirus Updates, MRK's New Cancer Deals
by Kinjel Shah
AstraZeneca (AZN) resumes its coronavirus vaccine study in the United Kingdom. Merck (MRK) inks two oncology deals with Seattle Genetics.
No Rate Hike Until 2023: Here's How to Play With ETFs
by Sanghamitra Saha
As widely expected, the Fed held interest rates steady at a near-zero level in its latest meeting.
Bristol-Myers' Opdivo+Yevroy Application Gets EMA Validation
by Zacks Equity Research
Bristol Myers Squibb (BMY) gets EMA validation for a type II variation application for its Opdivo+Yervoy combination to treat previously untreated, unresectable malignant pleural mesothelioma.
Astrazeneca (AZN) Stock Moves -0.27%: What You Should Know
by Zacks Equity Research
Astrazeneca (AZN) closed the most recent trading day at $55.13, moving -0.27% from the previous trading session.
Novavax Expands Coronavirus Vaccine Manufacturing Deal in India
by Zacks Equity Research
Novavax (NVAX) amends its present contract with Serum Institute of India Private Limited to widen the manufacturing capacity of its COVID-19 vaccine candidate NVX-CoV2373 to 2 billion plus doses in 2021.
BioNTech Gets New Funding for Coronavirus Vaccine Development
by Zacks Equity Research
BioNTech (BNTX) receives grant of up to almost $445 million to support development and potential approval of its coronavirus vaccine candidate.
Why Is This the Right Time to Invest in Low-Volatility ETFs?
by Sanghamitra Saha
.S. markets may have bounced back at the news of AstraZeneca???s (AZN) resumption of its phase 3 trial, but gains have been limited as the fear factor remains in investors??? mind.
Stock Market News for Sep 15, 2020
by Zacks Equity Research
U.S. stock markets closed higher on Monday reversing some of the losses of the last week.
ETFs in Focus on Tug of War Between Bulls and Bears
by Sweta Killa
Both bull and bear ETFs are showing immense potential as abrupt changes in sentiments have raised the appeal for these products.
Pfizer Seeks to Raise Coronavirus Study Enrollment Target
by Zacks Equity Research
Pfizer (PFE) and its partner, BioNTech, are seeking FDA's approval to increase enrollment target in the late-stage study on their coronavirus vaccine candidate to diversify patient population.
6 Sector ETFs Surviving the Market Rout
by Sweta Killa
Amid the uncertainties, a few sectors have survived last week's turmoil. We have highlighted six of that could be compelling picks for the weeks ahead as long as volatility persists.
AstraZeneca Resumes UK Study on Coronavirus Vaccine Candidate
by Zacks Equity Research
AstraZeneca's (AZN) late-stages studies on its COVID-19 vaccine candidate, AZD1222 in U.K. resume after the Medicines Health Regulatory Authority confirms that it is safe to do so.
How to Hedge Market Volatility With ETFs
by Sweta Killa
Investors should apply some hedging techniques to their equity portfolio.
AstraZeneca's Fasenra Meets Endpoint in Rhinosinusitis Study
by Zacks Equity Research
AstraZeneca (AZN) is developing Fasenra under a clinical program as a potential treatment for chronic rhinosinusitis with nasal polyps.
Pharma Stock Roundup: AZN & PFE's Coronavirus Vaccine Updates & FDA Approvals
by Kinjel Shah
AstraZeneca (AZN) halts coronavirus vaccine study. FDA approves Roche (RHHBY) and Glaxo's (GSK) medicines.
Astrazeneca (AZN) Stock Moves -1.06%: What You Should Know
by Zacks Equity Research
Astrazeneca (AZN) closed at $53.07 in the latest trading session, marking a -1.06% move from the prior day.
The Zacks Analyst Blog Highlights: AZN, SFM, DVA, BIG and RCII
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AZN, SFM, DVA, BIG and RCII
Pfizer, BioNTech May Supply 200M Coronavirus Vaccine Doses in EU
by Zacks Equity Research
Pfizer (PFE) and BioNTech are in discussion with the European Commission to supply potentially 200 million doses of their COVID-19 vaccine BNT162b2 on approval.
Glaxo/Innoviva's Trelegy Ellipta Gets FDA Nod for Asthma
by Zacks Equity Research
With the approval for the asthma indication, Glaxo's (GSK) Trelegy becomes the first single inhaler triple therapy approved for the maintenance treatment of both asthma and COPD.
5 Stocks in ETF Witnessing a Spike on the Nasdaq Rebound
by Sweta Killa
After a three-day market rout, Wall Street rebounded in trading on Sep 9 as investors jumped in to buy beaten-down tech stocks.